

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY
(Present Status of Competition in the Pharmaceutical Industry)

THURSDAY, MARCH 20, 1975

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to notice, at 10 a.m., in room 2221, Dirksen Senate Office Building, Senator Gaylord Nelson (chairman of the full committee) presiding.

Present: Senators Nelson, Hathaway, and Abourezk.

Also present: Benjamin Gordon, staff economist, and Kay Klatt, research assistant.

Senator HATHAWAY (presiding). The subcommittee will come to order.

The first witnesses we have this morning are people representing the American Pharmaceutical Association. Dr. William Apple, I understand that you are going to make a statement and you have accompanying you—

Dr. APPLE. Dr. Feldmann and Mr. Roberts.

Senator HATHAWAY. You may proceed to read or summarize your statement.

STATEMENT OF DR. WILLIAM S. APPLE, EXECUTIVE DIRECTOR, AMERICAN PHARMACEUTICAL ASSOCIATION, ACCOMPANIED BY DR. EDWARD G. FELDMANN, ASSOCIATE EXECUTIVE DIRECTOR FOR SCIENTIFIC AFFAIRS; AND CARL ROBERTS, AMERICAN PHARMACEUTICAL ASSOCIATION ASSOCIATE GENERAL COUNSEL

Dr. APPLE. Senator Hathaway, I am Dr. William S. Apple, executive director of the American Pharmaceutical Association, which, as you know, is the national professional society of pharmacists in the United States. I am pleased, once again, to appear before this distinguished committee with my associates, Dr. Edward G. Feldmann, associate executive director for scientific affairs, and Mr. Carl Roberts, APhA associate general counsel.

This is the third opportunity which APhA has had to express its views directly to Congress regarding the Maximum Allowable Cost

(11663)